Ozempic vs Wegovy: Same Molecule, Different Approval, Different Bill

Ozempic and Wegovy both contain semaglutide and are made by Novo Nordisk. Their names are often used interchangeably, but the products differ in approved uses, presentations and dosing. The distinction is broader than diabetes versus weight loss: specific cardiovascular, kidney and liver indications also matter.

Start with the diagnosis and treatment your clinician recommends. Then check the exact product, formulation and insurance benefit rather than assuming a shared ingredient makes the options interchangeable.

Is Ozempic the same as Wegovy?

Ozempic's May 2026 label includes improving blood glucose in adults with type 2 diabetes, reducing major cardiovascular events in adults who also have established cardiovascular disease, and reducing sustained kidney-function decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease¹. It is not FDA-approved for weight management.

Wegovy's June 2026 label includes weight management and cardiovascular-risk reduction for injection and tablets, with different age and population criteria. Wegovy injection also has an accelerated-approval indication for adults with noncirrhotic MASH and F2 to F3 liver fibrosis; tablets do not carry that liver indication⁴. Our SELECT heart-health guide and Wegovy MASH guide explain the populations, outcomes and limitations behind those uses.

For weight-loss context, STEP 1 studied weekly semaglutide 2.4 mg and reported roughly 15% mean weight reduction at 68 weeks². That result describes the studied regimen and population, not the expected outcome from every semaglutide product or dose.

Why is Ozempic prescribed for weight loss?

FDA explains that clinicians generally may prescribe an approved medicine for an unapproved use when they judge it medically appropriate⁵. Such prescribing does not change the drug's approved indication or guarantee insurance coverage.

A Danish registry study documented Ozempic use beyond people with recorded type 2 diabetes during 2018–2023. Its authors concluded that off-label use explained only a minor part of the supply shortage³. That study is evidence about Denmark during a defined period, not a measure of current U.S. prescribing. Ask your clinician why an off-label option is being considered and what evidence, alternatives and practical constraints inform the decision.

Why would insurance cover Ozempic but not Wegovy?

A plan's drug benefit, the diagnosis and its authorization criteria can lead to different decisions for the two brands. Ask about the exact prescribed formulation and indication; do not assume an exclusion for weight-management treatment resolves coverage for a separately documented cardiovascular or liver indication.

Our prior-authorization guide separates clinical criteria, missing paperwork and benefit exclusions. The Medicare and Medicaid guide discusses additional program-specific questions. A clinician recommending treatment and an insurer agreeing to pay are different decisions. Request the plan's written requirements and the reason for any denial before paying for repeated applications or assuming another brand will be covered.

Dosing and price aren't identical either

Ozempic is injected weekly, with a maximum labeled dose of 2 mg for glycemic control; its kidney-risk-reduction regimen uses a 1 mg maintenance dose¹. Wegovy injection has indication-specific maintenance dosing. Its adult weight-management schedule permits 7.2 mg when additional weight reduction is clinically indicated after at least four weeks tolerating 2.4 mg. Wegovy tablets have a separate daily schedule⁴. The highest available strength is not automatically the dose appropriate for every approved use.

A change of brand or formulation needs a prescriber's plan. Do not convert doses yourself or combine semaglutide products. Our titration guide and Wegovy pill versus injection comparison explain questions to ask about the proposed regimen.

For budgeting, GLP-1 costs without insurance and the Wegovy and Ozempic price board distinguish medication offers from service fees and conditional rates. Compare the product actually prescribed. Compounded semaglutide is not either brand and is not FDA-approved; a lower advertised price does not establish equivalence for an approved indication⁶. Our compounding safety guide explains the additional questions.

What to establish before choosing a service

Confirm the diagnosis, exact medication, formulation, maintenance plan and follow-up needs with your clinician. Then establish the insurer's requirements and the full medication-plus-care price. An enrollment quiz or payment does not settle medical suitability.

For other medication discussions, Ozempic versus Mounjaro compares two diabetes brands, while Ozempic alternatives outlines additional options. Use those guides to prepare questions rather than selecting treatment solely by price. If you want to understand the contents of the device, what is in an Ozempic pen examines its labeled ingredients.